NASDAQ:SRZN Surrozen (SRZN) Stock Price, News & Analysis → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Free SRZN Stock Alerts $11.20 +0.11 (+0.99%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$10.49▼$11.2550-Day Range$8.61▼$11.4152-Week Range$4.50▼$16.19Volume11,805 shsAverage Volume15,300 shsMarket Capitalization$35.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Surrozen alerts: Email Address Surrozen MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingAcquiring Shares$3 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($11.87) to ($3.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 starsMedical Sector691st out of 904 stocksBiological Products, Except Diagnostic Industry118th out of 154 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Surrozen.Read more about Surrozen's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.66% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surrozen has recently decreased by 4.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSurrozen does not currently pay a dividend.Dividend GrowthSurrozen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SRZN. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Surrozen this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Surrozen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surrozen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,999,994.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders43.50% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surrozen's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Surrozen are expected to grow in the coming year, from ($11.87) to ($3.15) per share.Price to Book Value per Share RatioSurrozen has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Surrozen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I explain what this Keystone technology is… why it’s so critical to the future of not just AI but mankind… You must read this new presentation from Porter Stansberry. About Surrozen Stock (NASDAQ:SRZN)Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.Read More SRZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRZN Stock News HeadlinesJune 10 at 8:30 AM | globenewswire.comSurrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in MilanJune 4, 2024 | globenewswire.comSurrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated HepatitisMay 9, 2024 | globenewswire.comSurrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual MeetingMay 9, 2024 | investorplace.comSRZN Stock Earnings: Surrozen Beats EPS for Q1 2024May 8, 2024 | globenewswire.comSurrozen Provides First Quarter 2024 Financial Results and Business UpdateApril 18, 2024 | msn.comSurrozen files to sell 1.09M shares of common stock for holdersApril 18, 2024 | msn.comSurrozen (SRZN) Price Target Decreased by 40.00% to 20.66April 10, 2024 | uk.investing.comSurrozen director Tim Kutzkey acquires $3m in company stockApril 3, 2024 | globenewswire.comSurrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisApril 1, 2024 | msn.comU.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.60%April 1, 2024 | msn.comWhy Is Regenerative Medicine-Focused Surrozen Stock Trading Lower On Monday?April 1, 2024 | globenewswire.comSurrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq RulesApril 1, 2024 | globenewswire.comSurrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043February 8, 2024 | msn.comSurrozen Promotes Charles Williams to COO with CFO RoleJanuary 18, 2024 | finanznachrichten.deSurrozen, Inc.: Surrozen Provides Corporate Update on Clinical ProgramsJanuary 18, 2024 | ca.finance.yahoo.comSurrozen, Inc. (SRZNW) Stock Price, News, Quote & History - Yahoo FinanceJanuary 18, 2024 | finance.yahoo.comSurrozen Provides Corporate Update on Clinical ProgramsJanuary 3, 2024 | finance.yahoo.comWe're Keeping An Eye On Surrozen's (NASDAQ:SRZN) Cash Burn RateNovember 10, 2023 | stocknews.com3 Biotech Stocks to Watch in NovemberNovember 9, 2023 | msn.comSurrozen GAAP EPS of -$0.34 misses by $0.03November 8, 2023 | finance.yahoo.comSurrozen Provides Third Quarter 2023 Financial ResultsNovember 4, 2023 | morningstar.comSurrozen Inc Ordinary Shares SRZNAugust 20, 2023 | finanznachrichten.deSurrozen, Inc.: Surrozen Provides Second Quarter 2023 Financial ResultsAugust 10, 2023 | msn.comSurrozen GAAP EPS of -$0.31August 9, 2023 | finance.yahoo.comSurrozen Provides Second Quarter 2023 Financial ResultsSee More Headlines Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/11/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SRZN CUSIPN/A CIK1824893 Webwww.consonancehfw.com Phone650-489-9000FaxN/AEmployees42Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-85.54% Return on Assets-71.86% Debt Debt-to-Equity RatioN/A Current Ratio5.18 Quick Ratio5.18 Sales & Book Value Annual Sales$12.50 million Price / Sales2.87 Cash FlowN/A Price / Cash FlowN/A Book Value$18.39 per share Price / Book0.61Miscellaneous Outstanding Shares3,200,000Free Float1,807,000Market Cap$35.84 million OptionableNot Optionable Beta0.90 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Craig C. Parker M.B.A. (Age 62)CEO, President & Director Comp: $825.32kMr. Charles Williams (Age 44)CFO, COO & Corporate Secretary Comp: $611.03kDr. Li Yang Ph.D. (Age 55)Executive Vice President of Research Comp: $535.46kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Roeland Nusse Ph.D. (Age 74)Co-Founder & Member of Scientific Advisory Board Dr. Calvin Kuo M.D.Ph.D., Co-Founder & Member of Scientific AdvisorEsther JhunControllerMore ExecutivesKey CompetitorsOCA AcquisitionNASDAQ:OCAXMolecular PartnersNASDAQ:MOLNVaxartNASDAQ:VXRTCardiff OncologyNASDAQ:CRDFaTyr PharmaNASDAQ:LIFEView All CompetitorsInsidersTim KutzkeyBought 193,548 shares on 4/4/2024Total: $3.00 M ($15.50/share)View All Insider Transactions SRZN Stock Analysis - Frequently Asked Questions How have SRZN shares performed in 2024? Surrozen's stock was trading at $9.40 on January 1st, 2024. Since then, SRZN shares have increased by 19.1% and is now trading at $11.20. View the best growth stocks for 2024 here. When is Surrozen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our SRZN earnings forecast. How were Surrozen's earnings last quarter? Surrozen, Inc. (NASDAQ:SRZN) issued its earnings results on Wednesday, May, 8th. The company reported ($4.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.25) by $0.01. When did Surrozen's stock split? Shares of Surrozen reverse split on the morning of Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Surrozen? Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SRZN) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surrozen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.